Detail akcie H Lundbeck Rg-B online

Business Summary: H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, H Lundbeck A/S revenues increased 12% to DKR24.63B. Net income increased 2% to DKR3.19B. Revenues reflect USA segment increase of 17% to DKR13.29B, Europe segment increase of 13% to DKR5.82B, Other revenue segment increase of 6% to DKR387M. Dividend per share increased from DKR0.95 to DKR1.15. Basic Earnings per Share excluding Extraordinary Items increased from DKR3.17 to DKR3.22.